CompaniesAlgoTherapeutix

AlgoTherapeutix

defunct

About

Defunct Company

Areas of Focus

Categories

Rebranded/RenamedBankrupt, Merged, Sold, Renamed or Otherwise Defunct

Clinical Trials (2)

Total Trials

2

As Lead Sponsor

2

As Collaborator

0

Total Enrollment

290

By Phase

PHASE2: 2

By Status

COMPLETED: 1ACTIVE_NOT_RECRUITING: 1

Clinical Trials Pipeline2 trials

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Phase 1/2

Phase 2/3

N/A

Phase

Status

Role

Condition

2022

2023

2024

2025

Today

Hover over trial bars to see details

Recent Trials

NCT05917912Lead Sponsor

EASE (Efficacy of ATX01 Study in Erythromelalgia)

PHASE2Completed

14 participants

Started: Jun 14, 2023 · Completed: Feb 29, 2024

NCT05593614Lead Sponsor

Efficacy and Safety of ATX01 in Adult Patients With CIPN (Chemotherapy-induced Peripheral Neuropathy)

PHASE2Active, not recruiting

276 participants

Started: Feb 28, 2023 · Completed: Sep 30, 2024

AlgoTherapeutix | Biotech Hunter | Biotech Hunter